Combination therapy represents a key strategy for addressing the complex pathophysiology of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies involve multiple pathological mechanisms—tau aggregation, neuroinflammation, mitochondrial dysfunction, and proteostasis impairment—requiring multi-targeted approaches. This section covers synergistic drug combinations, the scientific basis for combination effects, clinical trial considerations, and recommended protocols for CBS/PSP patients.
CBS and PSP involve multiple pathological pathways that cannot be adequately addressed by single-agent therapies:
| Pathology | Single Target | Rationale for Combination |
|---|---|---|
| Tau aggregation | Tau ASO | Add anti-inflammatory, mitochondrial support |
| Neuroinflammation | CSF1R inhibitor | Add neurotrophic factors |
| Mitochondrial dysfunction | CoQ10 | Add creatine, NAD+ precursors |
| Proteostasis impairment | Rapamycin | Add tau aggregation inhibitors |
Additive effects: The combined effect equals the sum of individual effects
Synergistic effects: The combined effect exceeds the sum of individual effects
Synergistic combinations can achieve greater efficacy at lower doses, potentially reducing side effects.
Rationale: Tau pathology drives microglial activation; reducing tau burden decreases neuroinflammation.
Combination:
Evidence: Preclinical models show synergistic reduction in tau pathology and microglial activation
Rationale: Multiple mitochondrial pathways can be targeted simultaneously.
Combination:
Evidence: Creatine + CoQ10 show complementary mechanisms; synergistic neuroprotection in preclinical models
Rationale: Combining neurotrophic support with gene therapy provides sustained delivery.
Combination:
Rationale: Symptomatic treatment + disease modification may slow progression.
Combination:
Tests multiple factors simultaneously. Advantages: Tests all combinations, identifies interactions. Disadvantage: Large sample size required.
New drug added to stable background therapy. Advantages: Clinically relevant, ethical. Disadvantage: May miss synergistic effects.
Drugs administered in sequence. Advantages: Identifies optimal sequencing. Disadvantage: Long trial duration.
Anti-tau + Anti-inflammatory + Neurotrophic
Based on biomarker profiles
Basket trials, N-of-1 trials, adaptive designs